Sunifiram is one of the newest nootropics on the market showing very promising initial results. It falls into the ampakine family of nootropic supplements because it is an AMPA agonist.
Some reviews have suggested that it works similarly to Piracetam but it is over 1000 times more potent than Piracetam for the same dosage.
Sunifiram is highly effective at boosting memory function as well as attention span, learning, decision making and alertness.
Description:

Sunifiram (DM-235) is a piperazin derived ampakine drug which acts as a positive allosteric modulator of AMPA receptors, and has nootropic effects in animal studies with significantly higher potency than piracetam. A number of related compounds are known, the best known being unifiram (DM-232).
 
Application:

This enhancement by sunifiram is associated with an increase inphosphorylation of AMPAR through activation of protein kinase II(CaMKII) and an increase in phosphorylation of NMDAR through activation of protein kinase C α (PKCα). More specifically, sunifiram stimulates the glycine-binding site of NMDAR with concomitant PKCαactivation through Src kinase. Enhancement of PKCα activity triggers to potentiate hippocampal LTP through CaMKII activation. 
Sunifiram improves cognitive deficits via CaM kinase II andprotein kinase C activation.